Cetuximab in the treatment of rheumatoid arthritis

Journal of Clinical Rheumatology

Volumn 16, Issue 1, 2010, Pages 32-33

  Sullivan, Timothy ^a   Benjamin, Carolina G ^a   Kempf, Phillip W ^b   Deeken, John F ^a,c  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b VIRGINIA HOSPITAL CENTER   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

Author keywords

Cetuximab; Epidermal growth factor receptor; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; CELECOXIB; CETUXIMAB; CORTICOSTEROID; METHOTREXATE; PREDNISONE; RITUXIMAB;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG EFFECT; DRUG MECHANISM; FEMALE; HUMAN; LOADING DRUG DOSE; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; SQUAMOUS CELL CARCINOMA; SYMPTOM; TONGUE CARCINOMA;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS, SQUAMOUS CELL; RECEPTOR, EPIDERMAL GROWTH FACTOR; REMISSION INDUCTION; TONGUE NEOPLASMS;

EID: 77950366233     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/RHU.0b013e3181c8e176     Document Type: Article

References (10)

1. Baselga J. The EGFR as a target for anticancer therapy-focus on cetuximab. Eur J Cancer. 2001;37(suppl 4):S16-S22.
2. Shiozawa S, Shiozawa K, Tanaka Y, et al. Human epidermal growth factor for the stratification of synovial lining layer and neovascularization in rheumatoid arthritis. Am Rheum Dis. 1989;48:820-828.
3. Yarden Y. The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur J Cancer. 2001;37(suppl 4):S3-S8.
4. Yamane S, Ishida S, Hanamoto Y, et al. Proinflammatory role of amphiregu-lin, an epidermal growth factor family member whose expression is augmented in rheumatoid arthritis patients. J Inflamm (Lond). 2008;5:5.
5. Hiraoka K, Sasaguri Y, Komiya S, et al. Cell proliferation-related production of matrix metalloproteinases 1 (tissue collagenase) and 3 (stromelysin) by cultured human rheumatoid synovial fibroblasts. Biochem Int. 1992;27:1083-1091.
6. Hallbeck AL, Walz TM, Briheim K, et al. TGF-alpha and ErbB2 production in synovial joint tissue: increased expression in arthritic joints. Scand J Rheu-matol. 2005;34:204-211.
7. Kusada J, Otsuka T, Matsui N, et al. Immuno-reactive human epidermal growth factor (h-EGF) in rheumatoid synovial fluids. Nippon Seikeigeka Gakkai Zasshi. 1993;67:859-865.
8. Satoh K, Kikuchi S, Sekimata M, et al. Involvement of ErbB-2 in rheumatoid synovial cell growth. Arthritis Rheum. 2001;44:260-265.
9. Kameda H, Ishigami H, Suzuki M, et al. Imatinib mesylate inhibits proliferation of rheumatoid synovial fibroblast-like cells and phosphorylation of Gab adapter proteins activated by platelet-derived growth factor. Clin Exp Immunol. 2006;144:335-341.
10. Kurai J, Chikumi H, Hashimoto K, et al. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res. 2007;13:1552-1561.